Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
Authors
Keywords
Lung cancer, Immune checkpoint inhibitors, Advanced cancer, NSCLC, Biomarker, PD-L1, Prognostic, Total metabolic tumour volume, [18F]FDG PET/CT, Predictive, MTV
Journal
EUROPEAN JOURNAL OF CANCER
Volume 150, Issue -, Pages 99-107
Publisher
Elsevier BV
Online
2021-04-21
DOI
10.1016/j.ejca.2021.03.020
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
- (2020) Francesco Facchinetti et al. EUROPEAN JOURNAL OF CANCER
- 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
- (2020) Giulia Polverari et al. Cancers
- ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
- (2020) Filippo G. Dall’Olio et al. LUNG CANCER
- Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
- (2019) MASAHIRO KATSURADA et al. ANTICANCER RESEARCH
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer
- (2018) Alexander L. Chin et al. Clinical Lung Cancer
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
- (2018) Benjamin Houdu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
- (2017) Etienne Giroux Leprieur et al. EUROPEAN JOURNAL OF CANCER
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
- (2016) Anne Winther-Larsen et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis
- (2014) Hyung-Jun Im et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- (2014) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Inter-observer reproducibility of semi-automatic tumor diameter measurement and volumetric analysis in patients with lung cancer
- (2013) J. Dinkel et al. LUNG CANCER
- Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer
- (2012) Hao Zhang et al. International Journal of Computer Assisted Radiology and Surgery
- Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
- (2011) Shengri Liao et al. ACADEMIC RADIOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started